On the heels of an announcement about expanded testing capabilities, Empire Genomics LLC of Buffalo said this week it will develop a genomic companion diagnostic test for multiple myeloma using a new federal grant from the National Cancer Institute within the National Institutes of Health.
The Phase I grant comes through the Small Business Innovation Research (SBIR) program, which awards up to $150,000 during the first phase to support development of innovative ideas. The company will also be eligible for a Phase II award up to $1 million.
The company plans to use the funds to further develop its licensed technology to investigate methods in genomics to predict MM patient response to therapeutic treatments.
Based on the Buffalo Niagara Medical Campus, the company offers molecular genomic testing with a specialization in oncology and personalized medicine.
Earlier this week, the company announced it had acquired the exclusive license to technology from Cornell University, with which it will develop a molecular diagnostic test to help diagnose and treat patients with neuroendocrine prostate cancer (NEPC).